Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon

Abstract

Get full access to this article

View all access options for this article.

References

Goundry

Bell

Langtree

Moorthy

. Diagnosis and management of Raynaud’s phenomenon. BMJ 2012; 344: 1–8.

Wong

Favaloro

. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost 2008; 34: 295–304.

Mosca

Tani

Neri

Baldini

Bombardieri

. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006; 6: 1–4.

Kawald

Burmester

Huscher

Sunderkotter

Riemekasten

. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008; 35: 1830–1837.

Zulian

Corona

Gerloni

. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology 2004; 43: 229–233.

Shouval

Mukamel

Zulian

. Iloprost treatment for refractory Raynaud’s phenomenon in two infants. Clin Exp Rheumatol 2008; 26: 105–107.

Zulian

Costantını

Montesco

Schıavon

Zacchello

. Successful treatment of gangrene in systemic necrotizing vasculitis with iloprost. Br J Rheumatol 1998; 37: 228–230.